| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
It is wished a curative treatment of the chronic renal impairment is developed.DFAT with nature like mesenchymal stem cells was developed in Nippon University.
We transported DAFT in a chronic renal impairment model through caudal vein. As a result, ANCA-related nephritis mice were improved, but were not improved in nephropathy rat models with the adriamycin. TSG-6 has anti-inflammatory action. In the former case, TSG6 significantly developed in lung and kidney. When we knocked down TSG6 expression, the effect was canceled. The mechanism of the renal failure improvement was regarded as immunoregulation effects. The DFAT cell transplantation was thought to be able to apply a clinic to autoimmune nephritis.
|
